Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration

Drug Metabolism and Disposition

Volumn 39, Issue 12, 2011, Pages 2275-2282

  Stevens, Jasper ^a   Ploeger, Bart A ^b   Van Der Graaf, Piet H ^c   Danhof, Meindert ^a   De Lange, Elizabeth C M ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b LAP and P Consultants BV   (Netherlands)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

REMOXIPRIDE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BRAIN EXTRACELLULAR FLUID CONCENTRATION-TIME CURVE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG TRANSPORT; EXTRACELLULAR FLUID; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NONLINEAR SYSTEM; PHARMACOLOGICAL PARAMETERS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RAT;

ADMINISTRATION, INTRANASAL; ANIMALS; BIOLOGICAL AVAILABILITY; BRAIN; DOPAMINE ANTAGONISTS; INFUSIONS, INTRAVENOUS; MALE; NOSE; RATS; RATS, WISTAR; REMOXIPRIDE;

RATTUS;

EID: 81855206609     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.040782     Document Type: Article

References (33)

1. Ahlenius S, Ericson E, Hillegaart V, Nilsson LB, Salmi P, and Wijkström A (1997) In vivo effects of remoxipride and aromatic ring metabolites in the rat. J Pharmacol Exp Ther 283:1356-1366. (Pubitemid 28016511)
2. Bagger MA and Bechgaard E (2004) The potential of nasal application for delivery to the central brain-a microdialysis study of fluorescein in rats. Eur J Pharm Sci 21:235-242. (Pubitemid 38156160)
3. Baker H and Spencer RF (1986) Transneuronal transport of peroxidase-conjugated wheat germ agglutinin (WGA-HRP) from the olfactory epithelium to the brain of the adult rat. Exp Brain Res 63:461-473. (Pubitemid 16036221)
4. Beal SL and Sheiner BL (1992) NONMEM User's Guide, Part 1, University of California at San Francisco, San Francisco.
5. Chaurasia CS, Müller M, Bashaw ED, Benfeldt E, Bolinder J, Bullock R, Bungay PM, DeLange EC, Derendorf H, Elmquist WF, et al. (2007) AAPS-FDA Workshop White Paper: microdialysis principles, application, and regulatory perspectives. J Clin Pharmacol 47:589-603. (Pubitemid 46632149)
6. Chien WY, Su KSE, and Chang SF (1989) Nasal Systemic Drug Delivery, Marcel Dekker Inc., New York.
7. Danhof M, de Lange EC, Della Pasqua OE, Ploeger BA, and Voskuyl RA (2008) Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol Sci 29:186-191.
8. de Lange EC, Bouw MR, Mandema JW, Danhof M, de Boer AG, and Breimer DD (1995) Application of intracerebral microdialysis to study regional distribution kinetics of drugs in rat brain. Br J Pharmacol 116:2538-2544.
9. de Lange EC and Danhof M (2002) Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin Pharmacokinet 41:691-703.
10. de Lange EC, de Boer BA, and Breimer DD (1999) Microdialysis for pharmacokinetic analysis of drug transport to the brain. Adv Drug Deliv Rev 36:211-227.
11. de Lange EC, Ravenstijn PG, Groenendaal D, and van Steeg TJ (2005) Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic- pharmacodynamic modeling. AAPS J 7:E532-E543.
12. Del Bigio MR (1995) The ependyma: a protective barrier between brain and cerebrospinal fluid. Glia 14:1-13.
13. Dhuria SV, Hanson LR, and Frey WH 2nd (2010) Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 99:1654-1673.
14. Farde L and von Bahr C (1990) Distribution of remoxipride to the human brain and central D2-dopamine receptor binding examined in vivo by PET. Acta Psychiatr Scand Suppl 358:67-71. (Pubitemid 20297823)
15. Frey WH, Liu J, Chen X, Thorne RG, Fawcett JR, Ala TA, and Rahman Y (1997) Delivery of 125-I-NGF to the brain via the olfactory route. Drug Deliv 4:87-92. (Pubitemid 27276124)
16. Graff CL and Pollack GM (2005) Nasal drug administration: potential for targeted central nervous system delivery. J Pharm Sci 94:1187-1195. (Pubitemid 40904183)
17. Illum L (2004) Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 56:3-17.
18. Jansson B and Björk E (2002) Visualization of in vivo olfactory uptake and transfer using fluorescein dextran. J Drug Target 10:379-386.
19. Jeffrey P and Summerfield S (2010) Assessment of the blood-brain barrier in CNS drug discovery. Neurobiol Dis 37:33-37.
20. Jolivalt C, Minn A, Vincent-Viry M, Galteau MM, and Siest G (1995) Dextromethorphan O-demethylase activity in rat brain microsomes. Neuroscience Lett 187:65-68.
21. Köhler C, Hall H, Magnusson O, Lewander T, and Gustafsson K (1990) Biochemical pharmacology of the atypical neuroleptic remoxipride. Acta Psychiatr Scand Suppl 358:27-36. (Pubitemid 20297813)
22. Moghaddam B and Bunney BS (1989) Ionic composition of microdialysis perfusing solution alters the pharmacological responsiveness and basal outflow of striatal dopamine. J Neurochem 53:652-654. (Pubitemid 19186107)
23. Nilsson LB (1998) High sensitivity determination of the remoxipride hydroquinone metabolite NCQ-344 in plasma by coupled column reversed-phase liquid chromatography and electrochemical detection. Biomed Chromatogr 12:65-68.
24. Ogren SO, Lundström J, Nilsson LB, and Widman M (1993) Dopamine D2 blocking activity and plasma concentrations of remoxipride and its main metabolites in the rat. J Neural Transm Gen Sect 93:187-203. (Pubitemid 23272407)
25. Philpott N, Marsh JCW, Gordon-Smith EC, Bolton JS, Laidlaw ST, Snowden JA, and Brown MJ (1993) Aplastic anaemia and remoxipride. Lancet 342:1244-1245.
26. Post TM, Freijer JI, Ploeger BA, and Danhof M (2008) Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn 35:185-202.
27. Stevens J, Suidgeest E, van der Graaf PH, Danhof M, and de Lange EC (2009) A new minimal-stress freely-moving rat model for preclinical studies on intranasal administration of CNS drugs. Pharm Res 26:1911-1917.
28. Stevens J, van den Berg DJ, de Ridder S, Niederländer HA, van der Graaf PH, Danhof M, and de Lange EC (2010) Online solid phase extraction with liquid chromatography-tandem mass spectrometry to analyze remoxipride in small plasma-, brain homogenate-, and brain microdialysate samples. J Chromatogr B Analyt Technol Biomed Life Sci 878:969 -975.
29. van den Berg MP, Verhoef JC, Romeijn SG, and Merkus FW (2004) Uptake of estradiol or progesterone into the CSF following intranasal and intravenous delivery in rats. Eur J Pharm Biopharm 58:131-135. (Pubitemid 38781013)
30. Watson J, Wright S, Lucas A, Clarke KL, Viggers J, Cheetham S, Jeffrey P, Porter R, and Read KD (2009) Receptor occupancy and brain free fraction. Drug Metab Dispos 37:753-760.
31. Widerlöv E, Andersson U, von Bahr C, and Nilsson MI (1991) Pharmacokinetics and effects on prolactin of remoxipride in patients with tardive dyskinesia. Psychopharmacology (Berl) 103:46-49.
32. Widerlöv E, Termander B, and Nilsson MI (1989) Effect of urinary pH on the plasma and urinary kinetics of remoxipride in man. Eur J Clin Pharmacol 37:359-363. (Pubitemid 19276658)
33. Widman M, Nilsson LB, Bryske B, and Lundström J (1993) Disposition of remoxipride in different species. Species differences in metabolism. Arzneimittelforschung 43:287-297. (Pubitemid 23093231)